Publicaciones en colaboración con investigadores/as de Instituto Universitario de Oncologia del Principado de Asturias (20)

2020

  1. Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis

    International Journal of Cancer, Vol. 146, Núm. 2, pp. 373-387

2019

  1. Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

    Nucleic Acids Research, Vol. 47, Núm. 10, pp. 5016-5037

2018

  1. DNA methylation reprogramming of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase

    Epigenetics, Vol. 13, Núm. 1, pp. 95-107

  2. Epigenetic dysregulation of TET2 in human glioblastoma

    Oncotarget, Vol. 9, Núm. 40, pp. 25922-25934

  3. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes

    Nature, Vol. 554, Núm. 7690, pp. 62-68

  4. Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma

    Human Molecular Genetics, Vol. 27, Núm. 17, pp. 3046-3059

2017

  1. Cisplatin resistance in cell models evaluation of metallomic and biological predictive biomarkers to address early therapy failure

    Metallomics, Vol. 9, Núm. 5, pp. 564-574

  2. DNA methylation changes in human lung epithelia cells exposed to multi-walled carbon nanotubes

    Nanotoxicology, Vol. 11, Núm. 7, pp. 857-870

2016

  1. Age-associated hydroxymethylation in human bone-marrow mesenchymal stem cells

    Journal of Translational Medicine, Vol. 14, Núm. 1

  2. Susceptibility of lactic acid bacteria, bifidobacteria and other bacteria of intestinal origin to chemotherapeutic agents

    International Journal of Antimicrobial Agents, Vol. 48, Núm. 5, pp. 547-550

2013

  1. Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictiv

    Mutagenesis, Vol. 28, Núm. 1, pp. 39-48

2011

  1. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: A phase Ib study

    International Journal of Gynecological Cancer, Vol. 21, Núm. 3, pp. 478-485

  2. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies

    Investigational New Drugs, Vol. 29, Núm. 5, pp. 971-977

2006

  1. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: A GEIS study

    British Journal of Cancer, Vol. 94, Núm. 12, pp. 1797-1802

  2. Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 840, Núm. 1, pp. 44-49

2005

  1. Determination of thiamine and its phosphorylated forms in human plasma, erythrocytes and urine by HPLC and fluorescence detection: A preliminary study on cancer patients

    Journal of Pharmaceutical and Biomedical Analysis

  2. Development and validation of an ion pair HPLC method for gemcitabine and 2′,2′-difluoro-2′-deoxyuridine determination

    Analytica Chimica Acta, Vol. 528, Núm. 2, pp. 255-260

2004

  1. Determination of gemcitabine triphosphate in peripheral blood mononuclear cells by reverse-phase HPLC

    Chromatographia, Vol. 59, Núm. 7-8, pp. 493-496

  2. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation

    Cancer, Vol. 101, Núm. 10, pp. 2261-2269

  3. Protein kinase C θ is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias

    Clinical Cancer Research, Vol. 10, Núm. 12 I, pp. 4089-4095